Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.58 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.56 |
| ▸ | DRD2 | P14416 | 3/20 | 0.55 |
| ▸ | DRD3 | P35462 | 2/20 | 0.55 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.54 |
| ▸ | CCR3 | P51677 | 6/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2776292 | 0.85 | SLC6A2 (0.55) | MGLLCHRM4CCR3SLC6A2SLC6A4 | |
| SCHEMBL6507154 | 0.82 | DRD2 (0.59) | CHRM4DRD2DRD3NOTUM | |
| SCHEMBL7241082 | 0.81 | SLC6A2 (0.71) | MGLLCCR3SLC6A2SLC6A4 | |
| SCHEMBL6429226 | 0.80 | SLC6A2 (0.56) | CCR3SLC6A2SLC6A4 | |
| SCHEMBL6427438 | 0.78 | DRD2 (0.64) | CHRM4DRD2DRD3 | |
| SCHEMBL7508776 | 0.78 | CCR3 (0.73) | CCR3SLC6A2SLC6A4HTR2A | |
| SCHEMBL15800697 | 0.77 | DRD2 (0.79) | DRD2DRD3NOTUM | |
| SCHEMBL3051168 | 0.77 | DRD2 (0.64) | CHRM4DRD2DRD3NOTUM | |
| SCHEMBL12367085 | 0.77 | DRD2 (0.64) | CHRM4DRD2DRD3NOTUM | |
| SCHEMBL2732722 | 0.77 | DRD2 (0.64) | CHRM4DRD2DRD3NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050222408-A1 | Heterocyclic amides with anti-tuberculosis activity | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2005-10-06 | — | — | US | disclosed |
| US-20050026968-A1 | Heterocyclic amides with anti-tuberculosis activity | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2005-02-03 | — | — | US | disclosed |
| WO-2005007625-A2 | HETEROCYCLIC AMIDES WITH ANTI-TUBERCULOSIS ACTIVITY | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2005-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222408-A1 | Heterocyclic amides with anti-tuberculosis activity | TST, KAT5, NDUFS5 | MGLL 3757/4885CHRM4 1835/4885DRD2 944/4885 |
| US-20050026968-A1 | Heterocyclic amides with anti-tuberculosis activity | TST, KAT5, HDAC5 | MGLL 4162/4885CHRM4 2329/4885DRD2 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.